Administrative Core

行政核心

• 批准号: 8540392
• 负责人: JOSEPH M. DESIMONE
• 金额: $ 15.24万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-08-01 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8540392
• 关键词: Adherence; Area; Arts; Award; Basic Science; Breast; Budgets; CCNE1 gene; Caliber; Cancer Center; Cancer Patient; Clinic; Clinical; Clinical Sciences; Communication; Communities; Consultations; Dependency; Development; Disease Management; Doctor of Medicine; Doctor of Philosophy; Drug Delivery Systems; Education and Outreach; Effectiveness; Electronic Mail; Ensure; Environment; Funding; General Population; Goals; Institutes; Institution; Laboratories; Leadership; Malignant Neoplasms; Medical; Nanotechnology; North Carolina; Patient Care; Pharmacy Schools; Pharmacy facility; Play; Principal Investigator; Public Health; Recording of previous events; Research; Research Infrastructure; Research Personnel; Research Project Grants; Resources; Role; Schedule; Schools; Science; Scientist; Solutions; Specialized Program of Research Excellence; Technology; TimeLine; Translational Research; UNC Lineberger Comprehensive Cancer Center; Universities; Update; Work; anticancer research; drug development; experience; fight against; innovation; interest; medical schools; meetings; member; multidisciplinary; nanofabrication; nanomaterials; nanomedicine; nanoparticle; nanoscience; oncology; physical science; programs; success; web site; working group

Section N2. Research Team and Research Capabilities, Center Organization and Infrastructure (Administrative Core) 1) Research Team Outline the major strength of the team and specific senior investigators In the context of the proposed area of focus; Successful application of nanotechnology to cancer requires an interactive and diverse team with innovative and creative solutions. The innovation and goals proposed In our CCNE are challenging but mirror the strength of our researchers and partnerships, especially since our focus is to transition these nanotechnologies to cancer disease management. Our team reflects that focus and combines expertise in the basic science of nanotechnology working In concert with translational research oriented clinicians who can help both the broad and the specific research agenda to maximize a direct impact on patient care. In addition, we have successfully combined researchers from four schools on the UNC campus: the Schools of Medicine, Arts and Sciences, Pharmacy and Public Health. This diversity of expertise and interests will help to ensure the success of our program. Our research team is led by Co-Principal Investigators, Joseph M. DeSimone, Ph.D. and Joel Tepper, M.D., who bring extensive experience in scientific leadership across the continuum from basic science to clinical development. We have emphasized this bridging of basic and clinical sciences throughout our proposal to demonstrate our understanding of and commitment to the challenge of bringing nanotechnology applications to cancer patients. Our projects feature nanotechnologies that are singular to the University of North Carolina at Chapel Hill, build on innovative ideas that have originated within our group, and reflect the highest caliber of scientists who discovered and developed them. We are confident that our mix of ideas, people and technologies is ideally suited to deliver on the promise of Nanomedicine. The University of North Carolina at Chapel Hill prides itself on being a leading institute in both medical and physical sciences and also providing and facilitating an environment of inter-disciplinary interactions. The cancer research community at UNC is anchored by the UNC Lineberger Comprehensive Cancer Center with a 35-year history. It is further strengthened by the presence of two NCI Specialized Programs of Research Excellence (SPOREs) in Breast and Gl cancer. The physical sciences aspects of our center are supported by the newly formed Institute for Nanomedicine, the Institute for Advanced Materials, Nanoscience and Technology (lAM) and the Chapel Hill Analytical and Nanofabrication Laboratory (CHANL). The Center for Nanotechnology in Drug Delivery and the Translational Oncology and Nanoparticle Drug Development Initiative (TONDDI) Lab at the Eshelman School of Pharmacy help transition nanomaterial discoveries toward the clinic. The $50 million/year University Cancer Research Fund (UCRF) and UNC's Clinical and Translational Science Award (CTSA) further enhance the entrepreneurial and translational aspects of our efforts of bringing relief to cancer patients. Our Center leadership will have all these resources to support a cohesive, stimulating, and effective CCNE. Our team and resources are discussed in more detail in the following sections.

第N2节。研究团队和研究能力，中心组织和基础设施 （行政核心） 1)研究小组概述该小组的主要力量和具体的高级研究人员在拟议的重点领域的背景下; 纳米技术在癌症中的成功应用需要一个具有创新和创造性解决方案的互动和多样化的团队。在我们的CCNE中提出的创新和目标具有挑战性，但反映了我们研究人员和合作伙伴的实力，特别是因为我们的重点是将这些纳米技术过渡到癌症疾病管理。我们的团队反映了这一重点，并结合了纳米技术基础科学的专业知识，与转化研究导向的临床医生合作，他们可以帮助广泛的 和具体的研究议程，以最大限度地直接影响病人护理。此外，我们已经成功地结合了研究人员从四所学校的校园：医学，艺术和科学，药学和公共卫生的学校。这种专业知识和兴趣的多样性将有助于确保我们计划的成功。 我们的研究团队由共同首席研究员Joseph M. DeSimone博士和乔尔·泰珀医学博士他们在从基础科学到临床开发的连续统一体中带来了丰富的科学领导经验。我们在整个提案中强调了基础科学和临床科学之间的这种联系，以表明我们对将纳米技术应用于生物医学的挑战的理解和承诺。 癌症患者。我们的项目具有独特的纳米技术，以查佩尔山的北卡罗来纳州大学为基础，建立在我们小组内部起源的创新思想上，并反映了发现和开发它们的科学家的最高水平。我们相信，我们的想法，人员和技术的组合非常适合实现纳米医学的承诺。 位于查佩尔山的北卡罗来纳州大学以其在医学和物理科学方面的领先研究所而自豪，并提供和促进跨学科互动的环境。癌症研究社区由拥有35年历史的Lineberger综合癌症中心（Lineberger Comprehensive Cancer Center）负责。它进一步加强了两个NCI卓越研究专业计划（SPORE）在乳腺癌和GI癌症的存在。我们中心的物理科学方面的支持， 新成立的纳米医学研究所、先进材料、纳米科学和技术研究所（lAM）和查佩尔山分析和纳米纤维实验室（CHANL）。药物输送纳米技术中心和Eshelman药学院的转化肿瘤学和纳米颗粒药物开发倡议（TONDDI）实验室帮助将纳米材料的发现过渡到临床。每年5000万美元的大学癌症研究基金（UCRF）和美国癌症研究所的临床和转化科学奖（CTSA）进一步加强了我们为癌症患者提供救济的努力的创业和转化方面。我们的中心领导层将拥有所有这些资源来支持一个有凝聚力的，激励性的和有效的CCNE。我们的团队和资源将在以下章节中详细讨论。